Prostate cancer decisions — 2025

The Board denied service connection for prostate cancer and bilateral hearing loss, and dismissed the appeal for a rating in excess of 10 percent for tinnitus.

The Board remands the claim for service connection of the cause of death to obtain a complete TERA memorandum and a VA examination opinion.

The Board remands the Veteran's claim for service connection for prostate cancer to cure pre-decisional duty to assist errors and obtain a TERA opinion, an ionizing radiation exposure development, and a direct service connection opinion.

The Board denied the Veteran's claim for service connection for prostate cancer, finding that there was no evidence of in-service exposure to herbicides and that the Veteran's prostate cancer is not related to his military service.

The Board granted service connection for diabetes mellitus, type II and prostate cancer residuals under the PACT Act but denied a compensable rating for hypertension.

The Board granted service connection for residuals of prostate cancer and Addison's disease, both linked to herbicide exposure during active duty.

The Board remands the claim for service connection for prostate cancer due to a duty to assist error in not properly verifying toxic exposure risk activities during service.

The Board denied the Veteran's claim for a total disability rating based on individual unemployability (TDIU) due to his service-connected disabilities, including prostate cancer residuals, hearing loss, tinnitus, and erectile dysfunction.

The Board denied the Veteran's claim for a total disability rating due to individual unemployability (TDIU) from June 4, 2022, to October 2, 2025, as his service-connected disabilities did not render him unable to secure or follow substantially gainful employment.

The Board denied an initial compensable rating for bilateral hearing loss and remanded the issue of entitlement to service connection for prostate cancer.

The Board denied service connection for gastrointestinal cancer other than esophageal cancer and stomach cancer, brain cancer, and prostate cancer. The issues of entitlement to service connection for esophageal cancer, metastatic esophageal cancer, lung cancer, stomach cancer, and liver cancer were remanded.

The Board remands the claim for service connection for prostate cancer and residuals to provide the Veteran with notice of his right to a hearing.

The Board denied the veteran's claims for service connection for prostate cancer, special monthly compensation based on aid and attendance, service connection for erectile dysfunction as secondary to prostate cancer, and special monthly compensation under 38 U.S.C. § 1114(k) due to loss of use of a creative organ.

The Board remands the claims for service connection for coronary artery disease and prostate cancer, to include as due to herbicide exposure or a medically unexplained chronic multi-symptom illness (MUCMI), for further development of the record.

The Board granted service connection for prostate cancer, finding that the Veteran's current condition is causally related to his in-service exposure.

The Board grants service connection for prostate cancer based on the Veteran's in-service exposure to toxic chemicals, specifically AFFF.

The appeal regarding the proposed reductions in ratings for prostate cancer and lung cancer, as well as the proposal to discontinue special monthly compensation, was dismissed due to lack of a final adjudicative determination.

The Board granted a 100 percent disability rating for prostate cancer and colorectal cancer from January 6, 2020, to April 30, 2020, and a 20 percent rating for bowel incontinence associated with colorectal cancer from May 1, 2020.

The appeal for service connection for the Veteran's prostate cancer was dismissed due to the Veteran's death.

The Board granted service connection for an acquired psychiatric disorder, to include PTSD. The other issues are remanded.